Characteristics of patients with rheumatoid arthritis that impact treatment satisfaction and adherence: subanalysis of data from Argentina, Chile, and Uruguay from the SENSE study
Abstract
Introduction: patients' needs and perspectives are determinants for the treatment of rheumatoid arthritis (RA). Objectives: to evaluate the impact of inadequate response to disease-modifying antirheumatic drugs (DMARDs) on treatment satisfaction, outcomes and perspectives of adult patients with inadequate control of moderate/high activity RA. Materials and methods: satisfaction was assessed using the TSQM v1.4 questionnaire. Data on quality of life, adherence and management strategies were collected. Results are presented for Argentina, Chile and Uruguay (n=202). Results: the mean of the TSQM global satisfaction score was 62.3±21.8. Eighty-three percent reported good adherence. The main expectations of treatment were "lasting relief of symptoms" and "less joint pain". The 53.47% of patients preferred an oral treatment; 75.74% chose a rapid onset of action. The least accepted side effect was "increased risk of malignant neoplasms". Fifty-five percent planned to rotate DMARD. Of these, advanced therapies were considered in only 84.7%. Most were open to a combination treatment, but 25.2% preferred not to use it. Conclusions: the results reaffirm the commitment to treat-to-target strategies, considering the individualization of therapeutic decisions in the regional context.References
I. Papadimitropoulos E, Brnabic A, Vorstenbosch E, Leonardi F, Moyano S, Gómez D. The burden of illness of rheumatoid arthritis in Latin America-A systematic literature review. Int J Rheum Dis 2022 Apr;25(4):405-421. doi: 10.1111/1756-185X.14295.
II. Gamboa-Cárdenas RV, Ugarte-Gil MF, Loreto M, Sacnun MP, Saurit V, Cardiel MH, et al. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clin Rheumatol 2019 Oct;38(10):2737-2746. doi: 10.1007/s10067-019-04618-x. Epub 2019 Jun 3. Erratum in: Clin Rheumatol. 2019 Aug 20;: PMID: 31161486.
III. Batko B, Batko K, Krzanowski M, Żuber Z. Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis. J Clin Med 2019 Sep 8;8(9):1416. doi: 10.3390/jcm8091416.
IV. Marengo MF, Suarez-Almazor ME. Improving treatment adherence in patients with rheumatoid arthritis: what are the options? Int J Clin Rheumtol 2015 Oct 1;10(5):345-356. doi: 10.2217/ijr.15.39.
V. Louder AM, Singh A, Saverno K, Cappelleri JC, Aten AJ, Koenig AS, Pasquale MK. Patient preferences regarding rheumatoid arthritis therapies: a conjoint analysis. Am Health Drug Benefits 2016 Apr;9(2):84-93.
VI. Ho MP, González JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, Hauber AB, Irony T. Incorporating patient-preference evidence into regulatory decision making. Surg Endosc 2015 Oct;29(10):2984-93. doi: 10.1007/s00464-014-4044-2.
VII. Food and Drug Administration. Patient preference information. Voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo requests, and inclusion in decision summaries and device labeling. Citado: 11 de Julio de 2022. Disponible en: https://bit.ly/3oMuMxa.
VIII. Medical Device Innovation Consortium. Patient preference study design. Qualitative steps. Citado: 11 de julio de 2022. Disponible en: https://bit.ly/3udQ2gx.
IX. Papadimitropoulos M, Mysler E, García EG, Lobosco S, Botello BS, Leonardi-Reyes F, Haynes G. Treatment patterns and satisfaction for rheumatoid arthritis patients in Latin America undergoing advanced therapy. Value in Health 2017; 20(9):PA891. doi: 10.1016/j.jval.2017.08.2679.
X. Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, Strangfeld A. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT. RMD Open 2020 Oct;6(3):e001290. doi: 10.1136/rmdopen-2020-001290.
XI. Jackson JL, Chamberlin J, Kroenke K. Predictors of patient satisfaction. Soc Sci Med 2001 Feb;52(4):609-20. doi: 10.1016/s0277-9536(00)00164-7.
XII. Smolen JS, Aletaha D. What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 2006 Nov-Dec;24(6 Suppl 43):S-7-13.
XIII. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, González J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health 2013 Mar-Apr;16(2):385-93. doi: 10.1016/j.jval.2012.11.007.
XIV. Chaparro del Moral R, Rillo OL, Benegas M, Correa M de los A, Citera G, Maldonado-Cocco JA, et al. Adherencia al tratamiento de pacientes con artritis reumatoidea que reciben medicamentos biológicos. Rev Argent Reumatol 2013;24(4):18-26.
XV. Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Janková R, et al. Treatment satisfaction, patient preferences, and the impact of suboptimal disease control in a large international rheumatoid arthritis cohort: SENSE Study. Patient Prefer Adherence 2021 Feb 17;15:359-373. doi: 10.2147/PPA.S289692.
XVI. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar;31(3):315-24. doi: 10.1002/art.1780310302..
XVII. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010 Sep;69(9):1580-8. doi: 10.1136/ard.2010.138461. Erratum in: Ann Rheum Dis 2010 Oct;69(10):1892. PMID: 20699241.
XVIII. Radawski C, Genovese MC, Hauber B, Nowell WB, Hollis K, Gaich CL, et al. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheumatol Ther 2019 Sep;6(3):461-471. doi: 10.1007/s40744-019-00168-5.
XIX. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) Measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 2003 Dec 16;1:79. doi: 10.1186/1477-7525-1-79.
XX. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980 Feb;23(2):137-45. doi: 10.1002/art.1780230202.
XXI. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992 Jun;30(6):473-83.
XXII. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis. Arthritis Res Ther 2010;12(5):R177. doi: 10.1186/ar3141.
XXIII. De Cuyper E, De Gucht V, Maes S, Van Camp Y, De Clerck LS. Determinants of methotrexate adherence in rheumatoid arthritis patients. Clin Rheumatol 2016 May;35(5):1335-9. doi: 10.1007/s10067-016-3182-4.
XXIV. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009 Sep;25(9):2303-10. doi: 10.1185/03007990903126833.
XXV. Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E. Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis. A subgroup analysis of Japanese patients from a large international cohort study (SENSE). PLoS One 2021 Nov 15;16(11):e0259389. doi: 10.1371/journal.pone.0259389.
XXVI. Taylor PC, Siridopoulos P, Ancuta C, Lagunes-Galindo I, de la Vega MC, Kalyoncu U, et al. POS0512 Differences in treatment satisfaction, patient preferences, and treatment patterns between European, South american, and Japanese patients with suboptimally controlled rheumatoid arthritis: a subgroup analysis of the SENSE study. Ann Rheum Dis 2021; 80:489-490. doi: 10.1136/annrheumdis-2021-eular.842.
XXVII. Yun H, Chen L, Xie F, Patel H, Boytsov N, Zhang X, Curtis JR. Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat-to-target principles? Results from the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. Arthritis Care Res (Hoboken) 2020 Feb;72(2):166-175. doi: 10.1002/acr.24083.
XXVIII. Fayad F, Ziade NR, Merheb G, Attoui S, Aiko A, Mroue K, Masri AF. Patient preferences for rheumatoid arthritis treatments: results from the national cross-sectional LERACS study. Patient Prefer Adherence 2018 Aug 31;12:1619-1625. doi: 10.2147/PPA.S168738.
XXIX. Alten R, Krüger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst G, Nolting HD. Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 2016 Nov 1;10:2217-2228. doi: 10.2147/PPA.S117774.
XXX. Durand C, Eldoma M, Marshall DA, Bansback N, Hazlewood GS. Patient preferences for disease-modifying antirheumatic drug treatment in rheumatoid arthritis: a systematic review. J Rheumatol 2020 Feb;47(2):176-187. doi: 10.3899/jrheum.181165.
XXXI. Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open. 2019 Jan 11;5(1):e000585. doi: 10.1136/rmdopen-2017-000585.
XXXII. Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford) 2002 Mar;41(3):253-61. doi: 10.1093/rheumatology/41.3.253.
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
